c-Jun N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity

被引:208
|
作者
Saito, Chieko [1 ]
Lemasters, John J. [2 ,3 ]
Jaeschke, Hartmut [1 ]
机构
[1] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA
[2] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA
[3] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA
基金
美国国家卫生研究院;
关键词
Acetaminophen; Hepatotoxicity; Mitochondria; JNK; SP600125; Bax; Oxidant stress; INDUCED LIVER-INJURY; TUMOR-NECROSIS-FACTOR; MITOCHONDRIAL PERMEABILITY TRANSITION; CULTURED MOUSE HEPATOCYTES; IN-VIVO; NH2-TERMINAL KINASE; CELL INJURY; BAX TRANSLOCATION; ONCOTIC NECROSIS; PROTECTIVE ROLE;
D O I
10.1016/j.taap.2010.04.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Acetaminophen (APAP) overdose, which causes liver injury in animals and humans, activates c-jun N-terminal kinase (JNK). Although it was shown that the JNK inhibitor SP600125 effectively reduced APAP hepatotoxicity, the mechanisms of protection remain unclear. C57BI/6 mice were treated with 10 mg/kg SP600125 or vehicle (8% dimethylsulfoxide) 1 h before 600 mg/kg APAP administration. APAP time-dependently induced JNK activation (detected by JNK phosphorylation). SP600125, but not the vehicle, reduced JNK activation. attenuated mitochondrial Bax translocation and prevented the mitochondrial release of apoptosis-inducing factor at 4-12 h. Nuclear DNA fragmentation, nitrotyrosine staining, tissue GSSG levels and liver injury (plasma ALT release and necrosis) were partially attenuated by the vehicle (-65%) and completely eliminated by SP600125 (-98%) at 6 and 12 h. Furthermore, SP600125 attenuated the increase of inducible nitric oxide synthase (iNOS) mRNA and protein. However, APAP did not enhance plasma nitrite + nitrate levels (NO formation): SP600125 had no effect on this parameter. The iNOS inhibitor L-NIL did not reduce NO formation or injury after APAP but prevented NO formation caused by endotoxin. Since SP600125 completely eliminated the increase in hepatic GSSG levels, an indicator of mitochondrial oxidant stress, it is concluded that the inhibition of peroxynitrite was mainly caused by reduced superoxide formation. Our data suggest that the JNK inhibitor SP600125 protects against APAP-induced liver injury in part by attenuation of mitochondrial Bax translocation but mainly by preventing mitochondrial oxidant stress and peroxynitrite formation and thereby preventing the mitochondrial permeability transition pore opening, a key event in APAP-induced cell necrosis. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:8 / 17
页数:10
相关论文
共 50 条
  • [1] Pathophysiological significance of c-jun N-terminal kinase in acetaminophen hepatotoxicity
    Du, Kuo
    Xie, Yuchao
    McGill, Mitchell R.
    Jaeschke, Hartmut
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (11) : 1769 - 1779
  • [2] Lower susceptibility of female mice to acetaminophen hepatotoxicity: Role of mitochondrial glutathione, oxidant stress and c-jun N-terminal kinase
    Du, Kuo
    Williams, C. David
    McGill, Mitchell R.
    Jaeschke, Hartmut
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2014, 281 (01) : 58 - 66
  • [3] Delayed Treatment With 4-Methylpyrazole Protects Against Acetaminophen Hepatotoxicity in Mice by Inhibition of c-Jun n-Terminal Kinase
    Akakpo, Jephte Y.
    Ramachandran, Anup
    Duan, Luqi
    Schaich, Matthew A.
    Jaeschke, Matthew W.
    Freudenthal, Bret D.
    Ding, Wen-Xing
    Rumack, Barry H.
    Jaeschke, Hartmut
    TOXICOLOGICAL SCIENCES, 2019, 170 (01) : 57 - 68
  • [4] Activated c-Jun N-terminal kinase is required for axon formation
    Oliva, Anthony A., Jr.
    Atkins, Coleen M.
    Copenagle, Lily
    Banker, Gary A.
    JOURNAL OF NEUROSCIENCE, 2006, 26 (37) : 9462 - 9470
  • [5] Mitochondrial protein adduct and superoxide generation are prerequisites for early activation of c-jun N-terminal kinase within the cytosol after an acetaminophen overdose in mice
    Nguyen, Nga T.
    Du, Kuo
    Akakpo, Jephte Y.
    Umbaugh, David S.
    Jaeschke, Hartmut
    Ramachandran, Anup
    TOXICOLOGY LETTERS, 2021, 338 : 21 - 31
  • [6] c-Jun N-terminal kinase pathways in diabetes
    Yang, Ruojing
    Trevillyan, James M.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (12) : 2702 - 2706
  • [7] c-Jun N-terminal kinase signaling in aging
    Li, Yihao
    You, Li
    Nepovimova, Eugenie
    Adam, Vojtech
    Heger, Zbynek
    Jomova, Klaudia
    Valko, Marian
    Wu, Qinghua
    Kuca, Kamil
    FRONTIERS IN AGING NEUROSCIENCE, 2024, 16
  • [8] c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1
    Tian, Xiaodong
    Traub, Benno
    Shi, Jingwei
    Huber, Nadine
    Schreiner, Stefan
    Chen, Guowei
    Zhou, Shaoxia
    Henne-Bruns, Doris
    Knippschild, Uwe
    Kornmann, Marko
    CANCER GENE THERAPY, 2022, 29 (01) : 73 - 86
  • [9] Recent Advances in c-Jun N-Terminal Kinase (JNK) Inhibitors
    Li, Gang
    Qi, Wenqing
    Li, Xiaoxun
    Zhao, Jinwu
    Luo, Meihua
    Chen, Jianjun
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (03) : 607 - 627
  • [10] c-Jun N-Terminal kinase signaling inhibitors under development
    Han S.-Y.
    Toxicological Research, 2008, 24 (2) : 93 - 100